Before matching | p value | After matching | p value | |||
---|---|---|---|---|---|---|
ChEI user (n = 73) | ChEI non-user (n = 38) | ChEI user (n = 25) | ChEI non-user (n = 25) | |||
Age, years | 70.8 ± 8.7 | 71.6 ± 7.5 | 0.608 | 71.0 ± 8.8 | 70.7 ± 8.2 | 0.908 |
Female | 45 (61.6) | 22 (57.9) | 0.427 | 15 (60.0) | 15 (60.0) | 1.000 |
Education, years | 11.4 ± 4.7 | 13.2 ± 3.8 | 0.045 | 12 [9; 16] | 14 [10; 16] | 0.889 |
Amyloid PET positivity | 53 (72.6) | 17 (44.7) | 0.004 | 14 (56.0) | 14 (56.0) | 1.000 |
Baseline MMSE | 23.4 ± 2.9 | 26.3 ± 2.3 | 0.000 | 25.0 [24.0; 27.0] | 26.0 [24.0; 27.0] | 0.709 |
Baseline CDR SOB | 2.5 ± 1.1 | 1.4 ± 0.8 | 0.000 | 1.5 [1.0; 3.0] | 1.5 [1.0; 2.0] | 0.738 |
APOEε4 carrier* | 33 (62.3) | 11 (42.3) | 0.076 | 15 (60.0) | 5 (31.2) | 0.012 |
Cholinesterase inhibitor | ||||||
Donepezil | 70 (95.9) | 24 (0.96) | ||||
Rivastigmine | 3 (4.1) | 1 (0.04) |